Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Aicardi-Goutieres syndrome Indication Strategy Report 2026: JAK1, Trials and Deals
24 July 2026
2026 Aicardi-Goutieres syndrome strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Vanishing white matter disease Indication Strategy Report 2026: EIF2B5, Trials and Deals
24 July 2026
2026 Vanishing white matter disease strategy: epidemiology, EIF2B5 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pelizaeus-Merzbacher disease Indication Strategy Report 2026: PLP1, Trials and Deals
24 July 2026
2026 Pelizaeus-Merzbacher disease strategy: epidemiology, PLP1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hereditary sensory and autonomic neuropathy Indication Strategy Report 2026: NGF, Trials and Deals
24 July 2026
2026 Hereditary sensory and autonomic neuropathy strategy: epidemiology, NGF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Charcot-Marie-Tooth disease type 2A Indication Strategy Report 2026: MFN2, Trials and Deals
24 July 2026
2026 Charcot-Marie-Tooth disease type 2A strategy: epidemiology, MFN2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Emery-Dreifuss muscular dystrophy Indication Strategy Report 2026: LMNA, Trials and Deals
24 July 2026
2026 Emery-Dreifuss muscular dystrophy strategy: epidemiology, LMNA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital muscular dystrophy Indication Strategy Report 2026: LAMA2, Trials and Deals
24 July 2026
2026 Congenital muscular dystrophy strategy: epidemiology, LAMA2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Oculopharyngeal muscular dystrophy Indication Strategy Report 2026: PABPN1, Trials and Deals
24 July 2026
2026 Oculopharyngeal muscular dystrophy strategy: epidemiology, PABPN1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Myotonic dystrophy type 1 Indication Strategy Report 2026: DMPK, Trials and Deals
24 July 2026
2026 Myotonic dystrophy type 1 strategy: epidemiology, DMPK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Facioscapulohumeral muscular dystrophy Indication Strategy Report 2026: DUX4, Trials and Deals
24 July 2026
2026 Facioscapulohumeral muscular dystrophy strategy: epidemiology, DUX4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Limb-girdle muscular dystrophy Indication Strategy Report 2026: FKRP, Trials and Deals
24 July 2026
2026 Limb-girdle muscular dystrophy strategy: epidemiology, FKRP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Paroxysmal kinesigenic dyskinesia Indication Strategy Report 2026: PRRT2, Trials and Deals
24 July 2026
2026 Paroxysmal kinesigenic dyskinesia strategy: epidemiology, PRRT2 biology, clinical competition, recent deals, unmet need and market attractiveness.